阿拉丁小分子抑制劑、激動劑、拮抗劑--血管生成信號通路(下)

來源: 上海阿拉丁生化科技股份有限公司   2021-1-29   訪問量:496評論(0)

r-box;">≥98%848942-61-05mg,10mg,50mg無細胞EGFR4 nMErbB23 nMErbB34 nMC127191CUDC-101≥98%1012054-59-910mg,25mg,50mg,100mg,250mgHDAC4.4 nMEGFR2.4 nMHER215.7 nMA126582AG-1478 (Tyrphostin AG-1478)≥98%153436-53-45mg,10mg,25mg,50mg無細胞EGFR3 nMP129384PD153035 HCl≥98%(HPLC)183322-45-410mg,50mg,250mg無細胞EGFR29 pM5.2 pMP125444Pelitinib≥98%257933-82-75mg,25mg,100mgEGFR3.5 nMSrc282 nMMEK/ERK800 nMErbB21255 nMB126145AC480 (BMS-599626)≥98%714971-09-25mg,10mg,25mg,100mgHER120 nMHER230 nMA126830AEE788 (NVP-AEE788)≥97%497839-62-05mg,25mg,100mgEGFR2 nMHER2/ErbB26 nMA127691AP26113≥98%1197958-12-55mg,10mg,25mg,ALKEGFRO125033OSI-420≥99%183320-51-61mg,5mg,10mg,50mg EGFR2 nMW127717WZ3146≥98%1214265-56-11mg,5mg,25mg,100mgEGFR(L858R)2 nMEGFR(E746_A750)2 nMA126334ARRY-380≥98%937265-83-31mg,5mg,10mg,50mg HER28 nMW126471WZ8040≥98%1214265-57-21mg,5mg,25mg,50mg EGFRA129426AST-1306 TsOH≥98%1050500-29-25mg,10mg,50mgEGFR0.5 nMErbB23 nMC124905CO-1686 (AVL-301)≥99%1374640-70-65mg,10mg,50mg,100mg無細胞EGFRL858R/T790M21.5 nMEGFRWT303.3 nMG106672金雀異黃酮分析標準品,≥98%446-72-020mg,1g,5gNIH-3T3細胞EGF12μM胰島素19 μMG106673金雀異黃酮97%446-72-0100mg,500mg,1g,5g,25gNIH-3T3細胞EGF12μM胰島素19 μMV129433Varlitinib≥96%845272-21-11mg,5mg,10mg,50mgErbB1(EGFR)7 nMErbB2(HER2)2 nMI129405Icotinib≥99%610798-31-75mg,10mg,50mg EGFR5 nMT126234TAK-285≥98%871026-44-71mg,5mg,10mg,50mgHER217 nMEGFR(HER1)23 nMW125072WHI-P154≥98%211555-04-310mg,50mgJAK31.8 μMD155111Daphnetin>90.0%(HPLC)486-35-150mg,100mg,250mg,1gEGFR7.67 μMPKA9.33 μMPKC25.01 μMP129447PD168393≥98%194423-15-910mg,50mg,250mg EGFR0.70 nMT129439Tyrphostin 9≥98%10537-47-025mg,50mg,100mg,500mgEGFR460 μMPDGFR0.5μMT129445Tyrphostin 23≥98%118409-57-710mg,50mg,250mg EGFR35 μMT162509酪氨酸激酶抑制劑 AG 494>98.0%(HPLC)(N)133550-35-320mg,100mgEGFR1.2 μMEGF6 μMO173511Olmutinib97%1353550-13-65mg,100mgPD153035PD153035≥98%153436-54-510mg,50mg,250mg EGFR5.2 pME126691EBE-A22-229476-53-35mg,10mg,25mg,50mg,100mg E107404(-)-表沒食子兒茶素沒食子酸98%989-51-5100mg,200mg,2.5g EGF/HER-2E107403(-)-表沒食子兒茶素沒食子酸分析標準品989-51-520mg,100mgEGF/HER-2E126633Erlotinib≥98%183321-74-6100mg,500mg,1g,5g EGFR2 nMD101144大黃酚97%481-74-350mg,250mg,1gEGFRmTORD101143大黃酚分析標準品,≥98%481-74-320mgEGFRmTORN159736Norcantharidin98%29745-04-81g,5g,25gc-MetEGFRB135922Butein≥98.0%(HPLC)487-52-5100mg,1g EGFR  

*HER2

項目號產品名稱規格CAS包裝細胞靶點IC50
L129338二對甲苯磺酸拉帕替尼(GW-572016)≥98%388082-77-725mg,100mg,250mg,500mg,1g無細胞ErbB29.2 nM
EGFR10.8 nM
N126132Neratinib (HKI-272)≥99%698387-09-65mg,25mg,100mg無細胞HER259 nM
EGFR92 nM
C125447Canertinib (CI-1033)≥98%267243-28-710mg,50mg,250mgEGFR1.5 nM
ErbB29.0 nM
L126696Lapatinib≥99%231277-92-225mg,100mg,250mg,500mg,1g,5gErbB29.2 nM
EGFR10.8 nM
C129397CP-724714≥99%537705-08-15mg,10mg,25mg,50mg HER2/ErbB210 nM
D129347Dacomitinib (PF299804, PF299)≥99%1110813-31-45mg,10mg,50mg,250mg EGFR6 nM
A129380AZD8931 (Sapitinib)≥98%848942-61-05mg,10mg,50mg無細胞EGFR4 nM
ErbB23 nM
ErbB34 nM
C127191CUDC-101≥98%1012054-59-910mg,25mg,50mg,10mmg,250mgHDAC4.4 nM
EGFR2.4 nM
HER215.7 nM
M129797Mubritinib (TAK 165)≥99%366017-09-610mg,50mg,250mgT-474細胞HER2/ErbB26 nM
B126145AC480 (BMS-599626)≥98%714971-09-25mg,10mg,25mg,100mgHER120 nM
HER230 nM
A126830AEE788 (NVP-AEE788)≥97%497839-62-05mg,25mg,100mgEGFR2 nM
HER2/ErbB26 nM
T126234TAK-285≥98%871026-44-71mg,5mg,10mg,50mgHER217 nM
EGFR(HER1)23 nM
T129799Tyrphostin AG 879≥98%148741-30-45mg,25mg,100mg HER2/ErbB21 μM
N133726去甲二氫愈創木酸≥95%500-38-91g,5gIGF-1R/HER2
L193141二甲苯磺酸拉帕替尼 一水合物0.98388082-78-81g,5gEGFR10.8 nM
ErbB29.2 nM
E107404(-)-表沒食子兒茶素沒食子酸98%989-51-5100mg,200mg,2.5g EGF/HER-2
E107403(-)-表沒食子兒茶素沒食子酸分析標準品989-51-520mg,100mg EGF/HER-2 

*HIF

產品號產品名稱規格CAS包裝細胞靶點IC50
M1259602-Methoxyestradiol (2-MeOE2)≥98%362-07-210mg,25mg,50mg,100mg,500mg
P101691芍藥苷≥98%(HPLC)23180-57-610mg,500mg,5g
P101690芍藥苷分析標準品,≥98%23180-57-620mg
F126178FG-4592≥98%808118-40-310mg,50mg,25mg HIF-α脯氨酰羥化酶
I127127IOX2≥98%931398-72-05mg,25mg,100mg無細胞PHD221 nM
V171541Vadadustat97%1000025-07-9100mg
N170064N-acetylcysteine amide98% (HPLC)38520-57-95mg,25mg
D136754DMOG≥98% (HPLC)89464-63-150mg,100mg,250mg,1g HIF prolyl hydroxylase

*Bcr-Abl

項目號產品名稱規格CAS包裝細胞靶點IC50ED50
D125110Dasatinib≥99%302962-49-825mg,100mg,500mg,1g,5g無細胞Abl<1 nM
Src0.8 nM
c-Kit79 nM
I129225Imatinib Mesylate (STI571)≥99%220127-57-1100mg,250mg,1g,5g,25gv-Abl0.6 μM
c-Kit0.1 μM
PDGFR0.1 μM
P127550Ponatinib (AP24534)≥99%943319-70-810mg,50mg,250mg無細胞Abl0.37 nM
PDGFRα1.1 nM
VEGFR21.5 nM
FGFR12.2 nM
Src5.4 nM
N126111Nilotinib (AMN-107)≥99%641571-10-025mg,100mg,250mg,1g小鼠骨髓祖細胞BCR-ABL<30 nM
D126182Danusertib (PHA-739358)≥98%827318-97-85mg,10mg,50mg無細胞Aurora A/B/C13 nM/79 nM/61 nM
Aurora A/B/C13 nM/79 nM/61 nM
Aurora A/B/C13 nM/79 nM/61 nM
B129232Bafetinib (INNO-406)≥98%859212-16-15mg,25mg,100mg無細胞Bcr-Abl5.8 nM
Lyn19 nM
K127169KW-2449≥98%1000669-72-65mg,25mg,100mg Flt36.6 nM
N127928NVP-BHG712≥98%940310-85-05mg,25mg,100mgEphB425 nM
c-Raf0.395 μM
c-Src1.266 μM
c-Abl1.667 μM
P126419PP121≥98%1092788-83-410mg,50mgPDGFR2 nM
Hck8 nM
mTOR10 nM
VEGFR212 nM
Src14 nM
Abl18 nM
DNA-PK60 nM
D126373DCC-2036 (Rebastinib)≥99%1020172-07-910mg,50mgAbl1(WT)0.8 nM
Abl1(T315I)4 nM
G129296GZD824≥99%1421783-64-35mg,25mgBcr-Abl(WT)0.34 nM
Bcr-Abl(T315I)0.68 nM
G126166GNF-2≥98%778270-11-45mg,25mg,50mg,250mg Bcr-Abl
G177569GNF-797%839706-07-9100mgM351T<5 nM
T315I61 nM
E255 V122 nM
G250E136 nM
c-Abl133 nM 

*FAK

項目號產品名稱規格CAS包裝細胞靶點IC50
P129811PF-00562271≥97%939791-38-55mg,10mg,50mg FAK1.5 nM
P126147PF-562271≥98%717907-75-05mg,10mg,50mg,100mg FAK1.5 nM
P129908PRT062607 (P505-15, BIIB057) HCl≥98%1370261-97-45mg,25mg無細胞Syk1 nM
P129814PF-573228≥98%869288-64-210mg,50mg無細胞FAK4 nM
T129808TAE226 (NVP-TAE226)≥99%761437-28-95mg,10mg,50mg FAK5.5 nM
P127543PF-03814735≥99%942487-16-31mg,5mg,10mg,50mgAurora A0.8 nM
Aurora B0.5 nM
P126394PND-1186≥98%1061353-68-15mg,25mg,100mg FAK1.5 nM
P127348PF-431396≥98%717906-29-110mg,50mgPYK211nM
FAK2 nM

*ALK

項目號產品名稱規格CAS包裝細胞靶點IC50Ki
C137735Crizotinib≥99%877399-52-510mg,50mg,100mg,250mg,500mg,1g,5g無細胞c-Met11 nM
ALK24 nM
T129819TAE684 (NVP-TAE684)≥98%761439-42-35mg,10mg,50mg無細胞ALK3 nM
C125242CH5424802≥98%1256580-46-75mg,25mg,100mg無細胞ALK1.9 nM
L127618LDK378≥99%1032900-25-65mg,25mg,100mg,250mg無細胞ALK0.2 nM
A127691AP26113≥98%1197958-12-55mg,10mg,25mg,50mg,100mgALK
EGFR
A125664AZD3463≥98%1356962-20-35mg,25mg,100mg ALK0.75 nM
A128022ASP3026≥98%1097917-15-15mg,25mg,100mg ALK 3.5 nM
P167337PF-06463922 acetate98% (HPLC)1454846-35-55mgROS1<0.02 nM
ALK (WT)<0.07 nM
ALK (L1196M) 0.7 nM

*FGFR

產品號產品名稱規格CAS包裝細胞靶點IC50
S129593Sorafenib Tosylate≥99%475207-59-110mg,50mg,250mg,1g,5g無細胞Raf-16 nM
B-Raf22 nM
VEGFR-290 nM
VEGFR-320 nM
PDGFR-β57 nM
Flt-359 nM
c-KIT68 nM
P127550Ponatinib (AP24534)≥99%943319-70-810mg,50mg,250mg無細胞Abl0.37 nM
PDGFRα1.1 nM
VEGFR21.5 nM
FGFR12.2 nM
Src5.4 nM
N127052BGJ398 (NVP-BGJ398)≥98%872511-34-75mg,25mg,10mg無細胞FGFR10.9 nM
FGFR21.4 nM
FGFR31 nM
N129725Nintedanib (BIBF 1120)≥98%656247-17-55mg,10mg,25mg,50mg,100mg,500mg無細胞VEGFR134 nM
VEGFR213 nM
VEGFR313 nM
FGFR169 nM
FGFR237 nM
FGFR3108 nM
PDGFRα59 nM
PDGFRβ65 nM
P129722Pazopanib HCl (GW786034 HCl)≥98%635702-64-625mg,100mg,250mg,1g無細胞VEGFR110 nM
VEGFR230 nM
VEGFR347 nM
PDGFR84 nM
FGFR74 nM
c-Kit140 nM
c-fms146 nM
P125865PD173074≥99%219580-11-75mg,10mg,50mgFGFR125 nM
VEGFR2100-200 nM
D126778Dovitinib (TKI-258, CHIR-258)≥99%405169-16-610mg,50mg,250mg無細胞FLT31 nM
c-Kit2 nM
A127209AZD4547≥99%1035270-39-35mg,10mg,25mg,50mg,100mg無細胞FGFR10.2 nM
FGFR22.5 nM
FGFR31.8 nM
D126182Danusertib (PHA-739358)≥98%827318-97-81mg,5mg,10mg,50mg無細胞Aurora A13 nM
Aurora B79 nM
Aurora C61 nM
L125518Lenvatinib (E7080)≥99%417716-92-85mg,10mg,50mg,100mg無細胞VEGFR2/KDR 4.0 nM
VEGFR3/FLT45.2 nM
B127317Brivanib (BMS-540215)≥98%649735-46-65mg,10mg,50mg VEGFR225 nM
E126318ENMD-2076≥99%934353-76-15mg,10mg,50mgAurora A14 nM
Flt31.86 nM
P125184Pazopanib≥99%444731-52-625mg,100mg,500mgGFR110 nM
VEGFR230 nM
VEGFR347 nM
PDGFR84 nM
FGFR74 nM
c-Kit140 nM
c-Fms/CSF1R146 nM
M129777MK-2461≥99%917879-39-11mg,5mg,10mg,50mg c-Met(WT/mutants)0.4-2.5 nM
B129764Brivanib Alaninate (BMS-582664)≥95%649735-63-710mg,50mgVEGFR225 nM
T129775Tyrphostin AG 1296≥99%146535-11-71mg,5mg,25mgPDGFR0.3-0.5 μM
Swiss 3T3細胞FGFR12.3 μM
c-Kit 1.8 μM
L126507LY2874455≥99%1254473-64-75mg,10mg,50mgFGFR12.8 nM
FGFR22.6 nM
FGFR36.4 nM
FGFR46 nM
VEGFR27 nM
F103701阿魏酸99%1135-24-65g,10g,25g,50g,100g,250g,500g,1kg
F103702阿魏酸分析標準品,≥99.5%(HPLC)1135-24-620mg
O173545ON-12330097%1357470-29-15mg,100mgCDK43.9 nM
Ark5/NUAK15 nM
PDGFRβ26 nM
FGFR126 nM
RET9.2 nM
Fyn11nM
P132694PD-166866≥98%(HPLC)192705-79-65mg,25mg,100mg FGFR152.4 nM
B174512BLU-993197%1538604-68-05mg,100mg FGFR43 nM

,

阿拉丁小分子抑制劑、激動劑、拮抗劑--血管生成信號通路(下)

血管生成

血管生成,即從已存在的血管中生成新血管。此通路是通過人體中存在的諸多互補和復雜的信號途徑調節的。正常情況下,血管生成的相關誘導劑和抑制劑之間保持平衡狀態。但對于創傷、缺氧或炎癥繼發等微環境破壞的條件下,此通路能做出迅速的應答。在各種慢性病理和腫瘤的情況下,血管生成的平衡狀態被打破,導致異常的血管生成或新生血管。

血管生成信號通路轉導過程

血管生成的激活導致促血管生成生長因子(VEGF、PDGF、FGF和TGF等)的釋放,這些因子將其受體結合到已有血管內的內皮細胞上,從而誘導PI3K/Akt、Erk1/2、Smad和Notch等多種途徑的信號轉導,引起內皮細胞增殖和遷移。內皮細胞利用基質金屬蛋白酶和整合素來消化細胞外基質,遷移到新的區域,在那里它們延長并形成管子,產生新的血管。
在腫瘤血管生成過程中,癌細胞刺激新血管的形成,為腫瘤輸送氧氣和營養。隨著腫瘤的生長,位于腫瘤中心的細胞缺氧,使得轉錄因子HIF-1α(缺氧誘導因子-1)穩定表達。該轉錄因子與HIF-1β結合上調幾種促血管生成基因的表達。此外,生長因子信號還刺激HIF-1活性,以維持生長細胞的氧穩態。

血管生成信號通路圖

產品列表

*JAK

項目號產品名稱規格CAS包裝細胞靶點IC50KiEC50
R126338Ruxolitinib (INCB018424)≥98%941678-49-55mg,25mg,50mg,100mg無細胞JAK13.3 nM
JAK22.8 nM
E129454Tofacitinib (CP-690550) Citrate≥99%540737-29-910mg,50mg,250mgJAK1112 nM
JAK220 nM
JAK31 nM
A126326AZD1480≥98%935666-88-95mg,25mg,100mg無細胞JAK20.26 nM
T126330Fedratinib (SAR302503, TG101348)≥98%936091-26-85mg,25mg,100mg無細胞JAK23 nM
J126663JANEX-198%202475-60-35mg,10mg,50mg JAK378 μM
W125855WHI-P97≥98%211555-05-410mg,50mgJAK-30.09 μM
C127224CYT387≥98%1056634-68-45mg,10mg,50mg,100mgJAK111 nM
JAK218 nM
T122330Tofacitinib≥98% (HPLC)477600-75-25mg,25mg,100mg,500mg,1g無細胞JAK31 nM
W129459WP1066≥98%857064-38-110mg,50mgHEL細胞JAK22.30 μM
STAT32.43 μM
T127523TG10120998%936091-14-45mg,25mg,100mg無細胞JAK26 nM
Flt325 nM
RET17 nM
L126490LY2784544≥98%1229236-86-55mg,10mg,50mg JAK23 nM
N129609NVP-BSK805 2HCl≥97%1092499-93-85mg,10mg,50mg JAK20.5 nM
B127687Baricitinib≥99%1187594-09-75mg,10mg,50mg無細胞JAK15.9 nM
JAK25.7 nM
A129464AZ 960≥99%905586-69-82mg,5mg,10mg JAK2<3 nM<0.45 nM
C129474CEP-33779≥99%1257704-57-65mg,10mg,50mg JAK21.8 nM
W125072WHI-P154≥98%211555-04-310mg,50mgJAK31.8 μM
X127151XL019≥99%945755-56-6 5mg,25mgJAK22.2 nM
S129613S-Ruxolitinib (INCB018424)≥99%941685-37-65mg,10mg,50mgJAK13.3 nM
JAK22.8 nM
Z129618ZM 39923 HCl≥98%1021868-92-710mg,50mg,250mgJAK14.4
JAK37.1
R171967Ruxolitinib phosphate salt97%1092939-17-7100mgJAK
C114054莪術醇分析標準品,≥98%4871-97-020mg     

*EGFR

項目號產品名稱規格CAS包裝細胞靶點IC50Ki
L126696Lapatinib≥99%231277-92-225mg,100mg,250mg,500mg,1g,5g ErbB29.2 nM
EGFR10.8 nM
L193141二甲苯磺酸拉帕替尼 一水合物0.98388082-78-81g,5gEGFR10.8 nM
ErbB29.2 nM
E129310Erlotinib HCl (OSI-744)≥99%183319-69-9100mg,500mg,1g,5g無細胞EGFR2 nM
G125799Gefitinib (ZD1839)≥99%184475-35-250mg,250mg,1g,5g,25g,100gNR6wtEGFRTyr117337 nM
Tyr99237nM
NR6WTyr117326 nM
Tyr99257 nM
L129338二對甲苯磺酸拉帕替尼(GW-572016)≥98%388082-77-725mg,100mg,250mg,500mg,1g無細胞ErbB29.2 nM
EGFR10.8 nM
V125180Vandetanib (ZD6474)≥99%443913-73-325mg,100mg,500mg無細胞VEGFR240 nM
VEGFR3110 nM
EGFR500 nM
N126132Neratinib (HKI-272)≥99%698387-09-65mg,25mg,100mg無細胞ER259 nM
EGFR92 nM
C125447Canertinib (CI-1033)≥98%267243-28-710mg,50mg,250mgEGFR1.5 nM
ErbB29.0 nM
A126525AG-490 (Tyrphostin B42)≥98%133550-30-820mg,50mg,250mg,1g無細胞EGFR0.1 μM
C129397CP-724714≥99%537705-08-15mg,10mg,25mg,50mg HER2/ErbB210 nM
D129347Dacomitinib (PF299804, PF299)≥99%1110813-31-45mg,10mg,50mg,250mg EGFR6 nM
W127713WZ4002≥98%1213269-23-810mg,50mg,100mgBaF3細胞系EGFR(L858R)2 nM
EGFR(T790M)8 nM
A129380AZD8931 (Sapitinib) 上海阿拉丁生化科技股份有限公司   商家主頁

地址:上海市浦東新區新金橋路196號6樓
聯系人:丁博士
電話:400-620-6333
傳真:021-50323701
Email:sale@aladdin-e.com

韩国免费无遮挡在线观看_日本牲交大片免费观看_毛片曰本女人牲交视频视频